ITM to Provide COMPETE Trial Insights at SNMMI 2025 Annual Meeting in Oral Presentation and Satellite Symposium
Symposium DetailsThe symposium, 'Pursuing the Art and Science of RPT: COMPETE Results and the Evolution of Dosimetry,' will take place on Sunday June 22, from 6:30 pm – 7:30 pm CDT. The symposium will feature an overview of the GEP-NET treatment landscape, including findings from the Phase 3 COMPETE trial, and perspectives on dosimetry standardization today and in the future. COMPETE evaluated n.c.a 177Lu-edotreotide (also known as ITM-11) in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NET) and ITM announced the positive Phase 3 results in March 2025.
Date and Time: Sunday, June 22, from 6:30 pm – 7:30 pm CDTLocation: Ernest N. Morial Convention Center, New Orleans, LA; Room R04-R05Speakers and Topics:
GEP-NET treatment landscape, COMPETE trial results, and COMPOSE trial designJonathan Strosberg, MD; Section Head, Neuroendocrine Division Program Chair, Gastrointestinal Department Oncology Research Program Moffitt Cancer Center
COMPETE dosimetry sub-study and the evolution of dosimetryJohn Sunderland, PhD; Professor of Radiology Nuclear Medicine Division University of Iowa
Dr. Celine Wilke Participates in Entrepreneur's PanelAs part of the SNMMI conference, Dr. Celine Wilke, ITM's Chief Medical Officer will participate in the 'Entrepreneur's Panel: Community Based Sites – Accelerating Clinical Trials and Expanding Access,' on Saturday, June 21, from 3:30 – 4:45 pm CDT.ITM will further be present at the conference with a booth (booth number: 1001) providing information on the company's latest innovations in radiopharmaceutical therapy (RPT), its pipeline of RPT therapeutics and the company's capabilities to produce high-quality medical radioisotopes for global partners and its own pipeline.
About the COMPETE TrialThe COMPETE trial evaluated 177Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic agent compared to everolimus, a targeted molecular therapy, in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This trial met its primary endpoint, with 177Lu-edotreotide demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus. 177Lu-edotreotide is also being evaluated in COMPOSE, a Phase 3 study in patients with well-differentiated, aggressive Grade 2 or Grade 3, SSTR-positive GEP-NET tumors.
About ITM Isotope Technologies Munich SEITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com
ITM ContactCorporate CommunicationsKathleen Noonan/Julia WestermeirPhone: +49 89 329 8986 1500Email: communications@itm-radiopharma.com
Investor RelationsBen OrzelekPhone: +49 89 329 8986 1009Email: investors@itm-radiopharma.com
Attachment
20250613_ITM to Provide COMPETE Trial Insights at SNMMI 2025 Annual Meeting in Oral Presentation and Satellite Symposium
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
OVB Holding Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Explore OVB Holding's Fair Values from the Community and select yours OVB Holding (ETR:O4B) Second Quarter 2025 Results Key Financial Results Revenue: €112.4m (up 10% from 2Q 2024). Net income: €1.57m (down 68% from 2Q 2024). Profit margin: 1.4% (down from 4.8% in 2Q 2024). The decrease in margin was driven by higher expenses. EPS: €0.11 (down from €0.34 in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period OVB Holding Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 5.1%. Earnings per share (EPS) missed analyst estimates by 63%. Looking ahead, revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 1.3% growth forecast for the Capital Markets industry in Germany. Performance of the German Capital Markets industry. The company's shares are down 3.6% from a week ago. Risk Analysis We don't want to rain on the parade too much, but we did also find 2 warning signs for OVB Holding (1 is significant!) that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Exploring 3 Undervalued European Small Caps With Insider Buying
As European markets experience a boost from strong corporate earnings and hopes for geopolitical resolutions, the pan-European STOXX Europe 600 Index has risen by 2.11%, signaling positive momentum across major stock indexes like Italy's FTSE MIB and Germany's DAX. In this environment of cautious optimism, identifying small-cap stocks with potential insider buying can be a strategic approach to uncovering opportunities in undervalued segments of the market. Top 10 Undervalued Small Caps With Insider Buying In Europe Name PE PS Discount to Fair Value Value Rating Kitwave Group 12.3x 0.3x 48.00% ★★★★★☆ Instabank 10.3x 3.0x 22.93% ★★★★★☆ Foxtons Group 11.0x 1.0x 39.41% ★★★★★☆ NCC Group NA 1.4x 10.35% ★★★★☆☆ CVS Group 44.9x 1.3x 38.37% ★★★★☆☆ Stelrad Group 40.4x 0.7x 39.35% ★★★☆☆☆ Oxford Instruments 40.7x 2.1x 17.08% ★★★☆☆☆ A.G. BARR 19.4x 1.8x 46.48% ★★★☆☆☆ SmartCraft 43.0x 7.7x 35.52% ★★★☆☆☆ Hoist Finance 10.5x 2.1x 17.53% ★★★☆☆☆ Click here to see the full list of 50 stocks from our Undervalued European Small Caps With Insider Buying screener. We're going to check out a few of the best picks from our screener tool. Breedon Group Simply Wall St Value Rating: ★★★★★★ Overview: Breedon Group is a construction materials company engaged in the production and supply of cement, aggregates, asphalt, and ready-mixed concrete across Great Britain, Ireland, and the United States with a market cap of approximately £1.5 billion. Operations: Breedon Group's revenue streams are primarily derived from its operations in Great Britain, Cement, Ireland, and the United States. The company has shown a notable trend in gross profit margin, which reached 82.31% as of December 2024. Operating expenses include significant allocations to general and administrative costs and non-operating expenses. PE: 14.4x Breedon Group, a notable player among smaller European companies, has caught attention with insider confidence shown through recent share purchases. Despite facing higher risk due to reliance on external borrowing for funding, the company reported sales of £815.9 million for H1 2025, up from £764.6 million last year. While net income dipped to £27.5 million from £34.1 million, an increased interim dividend of 4.75 pence per share signals potential growth prospects amidst financial challenges. Click here and access our complete valuation analysis report to understand the dynamics of Breedon Group. Gain insights into Breedon Group's past trends and performance with our Past report. Cint Group Simply Wall St Value Rating: ★★★☆☆☆ Overview: Cint Group operates a global software platform that facilitates market research and data collection, with a market capitalization of €0.57 billion. Operations: Cint Group generates revenue primarily through its Cint Exchange and Media Measurement segments. The company has seen a significant increase in gross profit margin, reaching 88.30% by June 2025, indicating improved cost efficiency relative to revenue. PE: 45.5x Cint Group, a small European company, has seen insider confidence with Patrick Comer purchasing 396,336 shares valued at €2.88 million in July 2025. Despite challenges like declining sales—€39.31 million in Q2 2025 compared to €42.07 million the previous year—their strategic partnerships are promising. The recent collaboration with Snowflake enhances customer data integration and privacy protection, while renewed agreements with Delineate and Kantar expand market reach and improve data quality delivery across global platforms. Dive into the specifics of Cint Group here with our thorough valuation report. Understand Cint Group's track record by examining our Past report. Platzer Fastigheter Holding Simply Wall St Value Rating: ★★★★☆☆ Overview: Platzer Fastigheter Holding is a real estate company primarily engaged in the ownership, management, and development of office, industrial, and logistics properties with a market cap of SEK 7.81 billion. Operations: The company's revenue primarily stems from its Offices segment, contributing SEK 1.32 billion, followed by Industrial/Logistics at SEK 410 million. Gross profit margin has shown variability, with a recent figure of 79.02%. Operating expenses are consistently around SEK 75 million in the latest period analyzed. PE: 22.0x Platzer Fastigheter Holding, a small European property firm, recently reported improved financials with second-quarter sales rising to SEK 431 million and net loss narrowing significantly from the previous year. Their strategic partnership in Sörred Logistic Park led to a lucrative property sale valued at SEK 385 million. Insider confidence is evident as Chairman Henrik Schoultz purchased 2,500 shares for approximately SEK 181,250 in June 2025. Despite relying on external borrowing for funding, Platzer's earnings are projected to grow by over 31% annually. Click here to discover the nuances of Platzer Fastigheter Holding with our detailed analytical valuation report. Assess Platzer Fastigheter Holding's past performance with our detailed historical performance reports. Seize The Opportunity Dive into all 50 of the Undervalued European Small Caps With Insider Buying we have identified here. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Interested In Other Possibilities? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include LSE:BREE OM:CINT and OM:PLAZ B. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Medscape
an hour ago
- Medscape
CPAP May Prevent BP Rise in Normotensive Sleep Apnea
TOPLINE: Among normotensive patients with severe obstructive sleep apnea (OSA) and a dipping blood pressure (BP) pattern, continuous positive airway pressure (CPAP) prevented increases in BP over a 3-month follow-up period, with significant reductions in nighttime diastolic BP compared with usual care. METHODOLOGY: Researchers conducted a randomized, prospective, controlled trial to assess the effect of CPAP on BP in normotensive individuals with severe OSA and a dipping BP pattern. Overall, 60 normotensive adult patients (mean age, 52.2 years; 66.7% men) with severe OSA (apnea-hypopnea index, ≥ 30 per hour) and a dipping BP pattern (reduction of ≥ 10% from daytime to nighttime BP) were randomly assigned to receive either CPAP or usual care for 12 weeks. Primary outcomes were changes from baseline to 3 months in ambulatory BP monitoring parameters: mean 24-hour BP; mean daytime and nighttime BP; 24-hour systolic and diastolic BP; and daytime and nighttime systolic and diastolic pressures. The secondary outcome was the change over 3 months in these ambulatory BP parameters according to adherence to CPAP, with a mean use of 4 or more hours per night defined as adequate adherence. TAKEAWAY: Over the study period, the CPAP group showed no significant change in ambulatory BP parameters, whereas the usual care group showed significant increases in 24-hour systolic BP, mean nighttime BP, and nighttime systolic and diastolic pressures. The CPAP group had a significantly greater reduction in nighttime diastolic BP than the usual care group (mean difference, -3.4 mm Hg; P = .015), but no other BP parameters differed significantly. Participants with inadequate adherence to CPAP had significantly greater increases in mean nighttime BP, nighttime systolic BP, and nighttime diastolic BP than those with adequate adherence. IN PRACTICE: 'Overall, this randomised trial provides novel insights into the potential benefits of CPAP therapy as a preventive measure for the development of hypertension. Further larger studies, including a greater proportion of women and potentially guided by polysomnography-based phenotypes, are needed to better understand the impact of OSA therapy in individuals with normal BP,' experts wrote in an accompanying editorial. SOURCE: This study was led by Adriano D.S. Targa and Gerard Torres, Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova-Santa Maria, Biomedical Research Institute of Lleida, Lleida, Spain. It was published online on July 24, 2025, in European Respiratory Journal. LIMITATIONS: The single-center design potentially limited the generalizability of the findings. The sample size was powered to detect a difference of ≥ 3 mm Hg, but the true effect in normotensive individuals with OSA may have been smaller, leaving the analysis underpowered. DISCLOSURES: This study was supported by the Instituto de Salud Carlos III, co-funded by the European Union, Sociedad Española de Neumología y Cirugía Torácica, and Diputació de Lleida. Some authors disclosed receiving financial support from Instituto de Salud Carlos III, co-funded by the European Union, and the Catalan Institution for Research and Advanced Studies Academia programme. The authors reported having no potential conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
